Pharma's Almanac

In case you missed it: in this Pharma's Almanac roundtable, a panel of industry experts weighs in on the most significant regulatory decision or guidance influencing biopharma in 2024 and beyond. Read the roundtable here: https://lnkd.in/g-yU58uV Our roundtable includes contributors from GBI Biomanufacturing, Lonza, MilliporeSigma, PPD, Samsung Biologics, Tedor Pharma Services, ADVI Health, Agilent Technologies, Astrea Bioseparations, Atomic AI, BioBridge Global, BioIVT, BIOSENIC S.A., Bruker BioSpin, Cellares, Cyclacel Limited, eClinical Solutions, Ellab - Validation & Monitoring Solutions, Evonik, Faeth Therapeutics, HDT Bio, Likarda, LGM Pharma, Medicus Pharma Ltd., Mission Bio, MOBILion Systems, Inc., Newfront, Norstella, OM1, Inc., OrganaBio, Organon, Ori Biotech, OzUK, Pharmatech Associates, a USP company, PointClickCare, ScaleReady, SCIEX, SCTbio, Sernova, ...(cont) #Regulatory #Biopharma #Roundtable

Biologics have revolutionized chronic disease treatment, yet their high costs pose financial challenges. Biosimilars, a cost-effective alternative, have emerged as a viable option for underserved global markets. In an exclusive article, Hugo Sotelo and Marcelo Criscuolo from BIOSIDUS delve into how biosimilars are enhancing global access to essential medications, thus forstering a more equitable healthcare system. Read the full article here: https://lnkd.in/gYSYd-qu #Biosimilars #Healthcare #Pharma #CDMOExcellence

Ensuring the safety, efficacy, and quality of biosimilars is crucial for their introduction to patients. In an exclusive article, Verónica Grimoldi, Corporate Director of Regulatory Affairs, R&D, and Clinical Research at BIOSIDUS, discusses the regulatory challenges within this market and highlights the importance of a robust regulatory framework for the launch of biosimilar medications worldwide. Read the full article here: https://lnkd.in/efEgwnnA #Regulatory #Biosimilars #CDMOExcellence #Pharma

Today, over 70% of the global population suffers from chronic diseases, often necessitating expensive biologic medications. In this exclusive article, Hugo Sotelo and Marcelo Criscuolo from BIOSIDUS share insights on the company's innovative solutions making biotherapeutics more accessible and affordable worldwide. Read the full article here: https://lnkd.in/eNpvcyWf #healthcareinnovation #Biosimilars #CDMOExcellence #Healthcare

In this roundtable from the close of 2023, we asked a panel of industry experts about the year's defining event in pharma/biopharma. Read the roundtable here: https://lnkd.in/da3fd6kj Our roundtable includes contributors from Be The Match BioTherapies, GBI Biomanufacturing, Lonza, Samsung Biologics, Tedor Pharma Services, Addimmune™, ADVI Health, Agilent Technologies, AnaptysBio, Astrea Bioseparations, Atomic AI, BioCina, BIOSENIC S.A., Bruker BioSpin, Cellares, CellProthera SAS, Click Therapeutics, Inc., CoRegen Inc., CRB, Cyclacel Pharmaceuticals, Inc., eClinical Solutions, Ellab - Validation & Monitoring Solutions, Elicio Therapeutics, Elixirgen Therapeutics, Inc., Enthought, Epocrates (use this one), Evonik, F2G, Faeth Therapeutics, HDT Bio, KBio, Likarda, LGM Pharma, Medicus Pharma Ltd., Mission Bio, MOBILion Systems, Inc., Newfront, Norstella, Nucleus RadioPharma, OM1, Inc., ... (cont.)

Discover innovative solutions advancing women's health beyond traditional boundaries. Fab Biopharma was founded to address under-researched conditions that disporportionately affect women. In this exclusive Q&A, Chia Chia Sun and Gardiner Smith, two of Fab Biopharma's founders, dive into the company's mission, vision, and unique expertise driving the development of effective treatments for women. Read the full article here: https://lnkd.in/em8aUq7f #WomenHealth #Biopharma #CDMO #CDMOExcellence

Discover the pivotal role of partnerships between global drug developers and CDMOs in driving project success. In this exclusive article, JC Ryan Lee, Senior Director of Sales Operations at Samsung Biologics, shares insights on fostering enduring, trust-driven collaborations. These partnerships empower CDMOs to enhance service excellence and advance their partners' business visions — and missions for patient care. Read the case study here: https://lnkd.in/epfmzFm5 #CDMOExcellence #Pharma #Partnership

Touchlight's enzymatically amplified dbDNA™ (doggybone DNA) tackles major hurdles in adeno-associated viral (AAV) vector manufacturing. In this exclusive article, Tom Merritt, Associate Director of dbDNA Applications for Viral Vectors Touchlight, shares how how Touchlight's innovation lowers the cost of AAV-based therapeutics and accelerates development pathways. Read the full article here: https://lnkd.in/eS3Nemp2 #AAV #Biotech #DNA #CDMO

Celebrating over 15 years of excellence, Coriolis Pharma stands out for its scientific expertise and commitment to accelerate client drug development timelines. In this exclusive Q&A, Silvia Steyrer-Gruber, Chief Executive Officer of Coriolis Pharma, shares insights into the company's pivotal role in the contract research and development sector. Read the full article here: https://lnkd.in/ewieACdj #CDMOExcellence #Pharma #DrugDevelopment

CD3, a protein complex and T cell co-receptor, serves as the primary target for bispecific antibodies. Bispecifics are attracting significant attention and investment due to their precise targeting capabilities. How do you foresee the evolution of bispecifics over time? #biopharma #bispecific #tcell #immunooncology Nice Insight